Food and Drug Administration
Biological Response Modifiers Advisory Committee
October 10, 2002
Briefing Information
Retroviral Gene Therapies for the Treatment of Patients with Severe Combined Immunodeficiency--Safety Issues, FDA htm pdf doc
Bibliography (revised) doc